Analysts Anticipate CymaBay Therapeutics Inc (NASDAQ:CBAY) to Post -$0.38 Earnings Per Share

Share on StockTwits

Equities analysts predict that CymaBay Therapeutics Inc (NASDAQ:CBAY) will post earnings of ($0.38) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for CymaBay Therapeutics’ earnings. The highest EPS estimate is ($0.31) and the lowest is ($0.45). CymaBay Therapeutics posted earnings per share of ($0.32) during the same quarter last year, which suggests a negative year over year growth rate of 18.8%. The business is scheduled to report its next earnings report on Thursday, February 27th.

On average, analysts expect that CymaBay Therapeutics will report full year earnings of ($1.49) per share for the current year, with EPS estimates ranging from ($1.56) to ($1.42). For the next year, analysts expect that the business will report earnings of ($0.98) per share, with EPS estimates ranging from ($1.59) to ($0.29). Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for CymaBay Therapeutics.

CymaBay Therapeutics (NASDAQ:CBAY) last announced its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.01).

Several research firms have weighed in on CBAY. Evercore ISI reiterated a “buy” rating and set a $12.00 target price on shares of CymaBay Therapeutics in a research note on Sunday, November 24th. Leerink Swann lowered shares of CymaBay Therapeutics to a “hold” rating and set a $2.50 price objective for the company. in a research note on Tuesday, November 26th. Stifel Nicolaus lowered shares of CymaBay Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 price objective for the company. in a research note on Monday, November 25th. Roth Capital lowered shares of CymaBay Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $22.00 to $2.00 in a research note on Tuesday, November 26th. Finally, Zacks Investment Research lowered shares of CymaBay Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $6.85.

In related news, CEO Sujal Shah bought 5,000 shares of CymaBay Therapeutics stock in a transaction on Monday, September 23rd. The shares were purchased at an average price of $5.53 per share, for a total transaction of $27,650.00. Following the completion of the acquisition, the chief executive officer now owns 111,900 shares in the company, valued at $618,807. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders have acquired 11,900 shares of company stock worth $59,600. Company insiders own 4.20% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of CBAY. Bank of Montreal Can lifted its holdings in shares of CymaBay Therapeutics by 1,372.0% in the second quarter. Bank of Montreal Can now owns 6,771 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 6,311 shares in the last quarter. Cambridge Investment Research Advisors Inc. acquired a new position in shares of CymaBay Therapeutics during the second quarter worth $80,000. Tower Research Capital LLC TRC acquired a new position in shares of CymaBay Therapeutics during the third quarter worth $61,000. Aperio Group LLC acquired a new position in shares of CymaBay Therapeutics during the second quarter worth $104,000. Finally, SG Americas Securities LLC acquired a new position in shares of CymaBay Therapeutics during the third quarter worth $85,000. Hedge funds and other institutional investors own 96.46% of the company’s stock.

CBAY stock traded up $0.17 during midday trading on Tuesday, reaching $1.89. 75,051 shares of the company’s stock traded hands, compared to its average volume of 3,930,757. The company has a market capitalization of $116.79 million, a P/E ratio of -1.51 and a beta of 1.04. The company has a debt-to-equity ratio of 0.01, a current ratio of 13.12 and a quick ratio of 13.12. CymaBay Therapeutics has a fifty-two week low of $1.29 and a fifty-two week high of $14.00. The business has a 50-day moving average price of $3.94 and a two-hundred day moving average price of $5.96.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Featured Article: Conference Calls

Get a free copy of the Zacks research report on CymaBay Therapeutics (CBAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Convergence Investment Partners LLC Sells 1,507 Shares of Verizon Communications Inc.
Convergence Investment Partners LLC Sells 1,507 Shares of Verizon Communications Inc.
Convergence Investment Partners LLC Sells 26,972 Shares of Intel Co.
Convergence Investment Partners LLC Sells 26,972 Shares of Intel Co.
Target Hospitality  Upgraded by Zacks Investment Research to Hold
Target Hospitality Upgraded by Zacks Investment Research to Hold
Travelers Companies  Now Covered by Citigroup
Travelers Companies Now Covered by Citigroup
Zacks Investment Research Upgrades Ultrapar Participacoes  to “Buy”
Zacks Investment Research Upgrades Ultrapar Participacoes to “Buy”
Visa  Now Covered by Macquarie
Visa Now Covered by Macquarie


© 2006-2020 Ticker Report